| Market Cap | $3.46B+206.6% |
| Revenue (ttm) | $378.98M |
| Net Income | -$220.54M |
| EPS | -$0.49 |
| Shares Out | 462.66M |
| PE Ratio | n/a |
| Forward PE | -65.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,994,305 |
| Open | $7.46 |
| Previous Close | $7.53 |
| Day's Range | $7.29 - $7.66 |
| 52-Week Range | $2.08 - $15.37 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | $14.50(+93.85%) |
| Earnings Date | Nov 5, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.
Analyst consensus
7 firms rating IOVA in the last 3 months, one vote each. Issuer-paid research is not counted.
$IOVA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IOVA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IOVA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IOVA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IOVA Revenue by Segment or Geography
| Amtagvi | $101.60M | 83.64% |
| Proleukin | $19.87M | 16.36% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IOVA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IOVA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IOVA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat with AMTAGVI sales growth, 2027 lung cancer filing target, lifileucel Fast Track status, and positive pipeline progress drive bullish sentiment.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.47% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 2.75% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 2.75% |
| BBP | Virtus Biotech ETF | 2.55% |
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 2.40% |
| MOON | Direxion Moonshot Innovators ETF | 1.95% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 1.81% |
| CANC | Tema Oncology ETF | 1.72% |
| BUZZ | VanEck Social Sentiment ETF | 1.65% |
| XBI | State Street SPDR S&P Biotech ETF | 0.87% |
| WDNA | WisdomTree BioRevolution Fund | 0.63% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.56% |
Weight is the stock’s share of each fund’s holdings.
